Daniel Umbricht, MD
xperimed LLC

Daniel Umbricht is a graduate of the University of Zurich Medical School, Switzerland. He received his training in general psychiatry at the Zucker Hillside Hospital, New York where he also completed a fellowship in clinical schizophrenia research under the mentorship of professors John Kane, Jeffrey Lieberman and Daniel Javitt.

Dr. Umbricht has held the ranks of assistant professor at the Albert Einstein School of Medicine and associate professor at the University of Zurich. While at the University of Zurich he was the recipient of a career development award by the Swiss National Science Foundation and received research grants from the National Alliance on Research in Schizophrenia and Depression (NARDAD). His research has focused on effects of atypical antipsychotics on information processing and the role of NMDA and 5-HT2A receptors in deficient information processing and cognitive deficits in schizophrenia including studies that spanned patients, healthy volunteers, non-human primates and mice. In addition, Daniel has conducted research in subjects at high-risk for schizophrenia that focused on predictors of transition to psychosis.

He joined Novartis Pharmaceuticals as Senior Translational Expert in Neuroscience where he led programs in addiction, anxiety, Alzheimer's disease and schizophrenia. Since 2008 he has held the position of Translational Medicine Expert in Neuroscience at F. Hoffmann – La Roche Ltd. In this function he led the early clinical development of compounds in schizophrenia, autism and major depression. In 2016 he became the head of the psychiatry/neurodevelopmental group in translational medicine neuroscience at Roche and in 2018 he was promoted to Distinguished Scientist and appointed as Global Head of Translational Medicine Neuroscience overseeing the development of the entire clinical portfolio that focused on schizophrenia, autism spectrum disorder, Alzheimer's disease, Parkinson's disease and multiple sclerosis.

After his departure from Roche in October 2020 he founded a consulting company and has been involved in the development of compounds for schizophrenia, major depression and rare neuropsychiatric disorders.

Daniel has authored more than 80 papers in high impact journals and is a widely recognized expert in

clinical development, clinical trial methodology, experimental medicine and translational neuroscience.